The FDA issued an emergency use authorization (EUA) for Evusheld (tixagevimab co-packaged with cilgavimab and administered together) for the pre-exposure prophylaxis of COVID-19. This product is only authorized for individuals not currently infected with COVID-19 who were recently exposed to infected individuals. Furthermore, this authorization requires that patients either have moderate-to-severely compromised immune systems or a history of severe adverse reactions to a COVID-19 vaccine. Evusheld is not a substitute for vaccination.
